142 related articles for article (PubMed ID: 18992059)
1. Importance of CsA drug monitoring in SCT recipients to minimize GVHD and maximize graft vs. leukemia.
Barkholt L
Pediatr Transplant; 2009 Jun; 13(4):400-3. PubMed ID: 18992059
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
[TBL] [Abstract][Full Text] [Related]
3. Effect of blood cyclosporine concentration on the outcome of hematopoietic stem cell transplantation from an HLA-matched sibling donor.
Kanda Y; Hyo R; Yamashita T; Fujimaki K; Oshima K; Onoda M; Mori T; Sakura T; Tanaka M; Sakai M; Taguchi J; Kurakawa M; Maruta A; Okamoto S; Sakamaki H;
Am J Hematol; 2006 Nov; 81(11):838-44. PubMed ID: 16888784
[TBL] [Abstract][Full Text] [Related]
4. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level.
Oshima K; Kanda Y; Nakasone H; Arai S; Nishimoto N; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Mar; 83(3):226-32. PubMed ID: 17918253
[TBL] [Abstract][Full Text] [Related]
5. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
[TBL] [Abstract][Full Text] [Related]
6. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
7. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
8. Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT.
Oshima K; Sato M; Terasako K; Kimura S; Okuda S; Kako S; Kanda Y
Bone Marrow Transplant; 2010 Apr; 45(4):781-2. PubMed ID: 19701249
[No Abstract] [Full Text] [Related]
9. Elevated blood drug levels obtained from indwelling silicon catheters during oral cyclosporine A administration.
Claviez A; Glass B; Dreger P; Suttorp M
Bone Marrow Transplant; 2002 Mar; 29(6):535-6. PubMed ID: 11960277
[TBL] [Abstract][Full Text] [Related]
10. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Bleyzac N
Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
[TBL] [Abstract][Full Text] [Related]
11. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect.
Huang XJ; Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX
Bone Marrow Transplant; 2009 Sep; 44(5):309-16. PubMed ID: 19234512
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the use of cyclosporin in allogeneic stem cell transplantation.
Duncan N; Craddock C
Bone Marrow Transplant; 2006 Aug; 38(3):169-74. PubMed ID: 16751787
[TBL] [Abstract][Full Text] [Related]
13. Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique.
Trifilio SM; Scheetz M; Borensztajn J; Mehta J
Clin Transplant; 2013; 27(1):154-61. PubMed ID: 23106694
[TBL] [Abstract][Full Text] [Related]
14. [Graft-versus-host disease: friend or foe?].
Kanda Y
Rinsho Ketsueki; 2008 Aug; 49(8):583-91. PubMed ID: 18800606
[No Abstract] [Full Text] [Related]
15. [Reevaluation of mechanisms of GVHD and GVL].
Teshima T
Rinsho Ketsueki; 2008 Aug; 49(8):592-7. PubMed ID: 18800607
[No Abstract] [Full Text] [Related]
16. Falsely elevated whole blood cyclosporine concentrations measured by an immunoassay with automated pretreatment.
Bartoli A; Molinaro M; Visai L
Ther Drug Monit; 2010 Dec; 32(6):791-2. PubMed ID: 21068651
[No Abstract] [Full Text] [Related]
17. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
18. Graft vs. host disease: pathology, prophylaxis and therapy: GVHD overview.
Weisdorf D
Best Pract Res Clin Haematol; 2008 Jun; 21(2):99-100. PubMed ID: 18503978
[No Abstract] [Full Text] [Related]
19. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
[TBL] [Abstract][Full Text] [Related]
20. Folinic acid administration following MTX as prophylaxis for GVHD.
Gratwohl A
Bone Marrow Transplant; 2009 Aug; 44(4):257. PubMed ID: 19204714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
